The Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium, organized by the Cardiovascular Research Foundation, recently concluded its session in San Diego, serving as a critical platform for the unveiling of clinical trial results that are expected to reshape the landscape of interventional cardiology. This year’s conference was punctuated by groundbreaking data from industry leaders Edwards Lifesciences, Medtronic, and Abbott, each presenting evidence that supports the expansion of minimally invasive therapies into broader patient populations. These developments come at a time when the medical technology sector is increasingly focused on early intervention and the refinement of devices to improve long-term patient outcomes while reducing the burden on healthcare systems.
The significance of the TCT conference lies in its role as a primary venue for late-breaking clinical trials. As the global population ages and the prevalence of structural heart disease and chronic hypertension rises, the data presented in San Diego provides a roadmap for regulatory approvals, insurance reimbursement shifts, and changes in the standard of care. The three standout studies from the event—PROGRESS for aortic stenosis, SPYRAL AFFIRM for hypertension, and VERITAS for stroke prevention—demonstrate a collective industry move toward addressing "moderate" or "uncontrolled" conditions before they progress to life-threatening stages.
Edwards Lifesciences and the Paradigm Shift in Aortic Stenosis Treatment
One of the most anticipated presentations at the symposium was the results of the PROGRESS trial, which evaluated the efficacy of Edwards Lifesciences’ Transcatheter Aortic Valve Replacement (TAVR) technology in patients with moderate aortic stenosis (AS). Historically, TAVR has been reserved for patients with severe symptomatic AS, moving over the last decade from a solution for high-risk surgical candidates to a standard treatment for low-risk patients. The PROGRESS trial represents the next frontier: treating patients before their condition becomes "severe" according to traditional hemodynamic measurements.
Aortic stenosis is a progressive condition characterized by the narrowing of the aortic valve, which restricts blood flow from the heart to the rest of the body. While clinical guidelines currently mandate "watchful waiting" or clinical surveillance for moderate disease, the PROGRESS trial challenged this status quo. The study enrolled 744 patients with an average age of 78, focusing on those who exhibited "at-risk" features such as cardiac damage or dysfunction despite not yet meeting the threshold for severe AS.
The findings, published simultaneously in The New England Journal of Medicine, were met with significant acclaim from the medical community. The study met its primary composite endpoint of death, heart failure events, or emergency valve intervention at two years. Specifically, the trial estimated an endpoint event in 16.7% of the TAVR group compared to 23.9% in the clinical surveillance group. Furthermore, the TAVR cohort showed an excellent safety profile, with zero instances of mortality or disabling stroke within the first 30 days post-procedure.
Dan Lippis, Edwards’ corporate vice president of TAVR, emphasized that the moderate AS population is estimated to be one to two times larger than the severe AS population. By providing "unequivocal validation" of TAVR’s benefits in this earlier stage, the study suggests a massive expansion of the addressable market. Analysts from J.P. Morgan and Stifel noted that these results could act as a catalyst for a revolution in how aortic valve disease is managed, potentially moving the clinical needle toward earlier intervention to prevent irreversible heart muscle damage. While some investors noted a slight variance in all-cause mortality—8.4% in the TAVR group versus 7.3% in the surveillance group—clinicians at the conference largely dismissed this as statistically insignificant in the context of the overall reduction in heart failure events and the inherent risks of the surveillance group eventually progressing to severe disease.
Medtronic and the Real-World Efficacy of Renal Denervation
The second major pillar of the TCT conference was the presentation of real-world data regarding Medtronic’s Symplicity Spyral renal denervation (RDN) system. Following its FDA approval in late 2023, the SPYRAL AFFIRM study was designed as a post-approval requirement to confirm the safety and efficacy of the procedure in a more diverse and representative patient population than previous pivotal trials.
Renal denervation is a minimally invasive procedure that uses radiofrequency energy to calm overactive nerves near the kidneys, which are often a root cause of chronic high blood pressure. The SPYRAL AFFIRM study focused on 594 U.S. patients with uncontrolled hypertension, a condition that affects millions globally and is a leading cause of stroke and kidney failure. A notable aspect of this study was its demographic reach: 45% of participants were women, 27% were Black, 11% were Hispanic, and 19% had Type 2 diabetes. This diversity is crucial, as hypertension disproportionately affects minority communities who have historically been underrepresented in clinical research.
The results, published in the journal Circulation: Cardiovascular Interventions, showed that the trial met its primary endpoint with statistically significant blood pressure reductions at six months. Nearly 90% of patients achieved an office systolic blood pressure reduction of at least 10 mm Hg. Additionally, many patients were able to reduce their reliance on antihypertensive medications, a significant quality-of-life improvement for those struggling with the side effects of multi-drug regimens.
Medtronic also announced that the FDA has approved a label update for the Symplicity Spyral system to include this additional clinical data. This update is expected to provide physicians with a more robust framework for recommending RDN to a broader range of patients. The "always-on" nature of RDN—providing blood pressure control 24 hours a day without the need for daily pill compliance—remains its strongest selling point in a healthcare environment where medication adherence is a persistent challenge.
Abbott’s Next-Generation Amulet 360 and the Battle for LAA Closure
The third major highlight involved Abbott’s VERITAS pivotal study, which examined the performance of the Amulet 360 Left Atrial Appendage (LAA) occluder. The LAA is a small pouch in the heart where blood clots often form in patients with atrial fibrillation (AFib). For patients who cannot tolerate long-term blood thinners, LAA closure devices offer a mechanical alternative to reduce the risk of ischemic stroke.
The Amulet 360 is Abbott’s next-generation iteration of the technology, featuring a redesigned implant capable of adapting to a wider range of patient anatomies. The device utilizes a "dual-seal" system—an internal lobe that plugs the appendage and an outer disc that covers the opening—to ensure complete closure. The VERITAS study, published in JACC: Cardiovascular Interventions, demonstrated that the device achieved complete closure in 96.3% of patients at the one-year mark, as evaluated by transesophageal echocardiography.
Safety metrics were equally compelling. The incidence of ischemic stroke or systemic embolism was just 1.8%, while major bleeding occurred in 6.6% of the study population. These figures are particularly relevant as Abbott seeks to gain ground on Boston Scientific’s Watchman device, which currently leads the LAA closure market. Analysts from BTIG suggested that the Amulet 360’s ability to treat more complex anatomies could allow Abbott to capture a larger share of the rapidly growing structural heart market.
Dr. DJ Lakkireddy, executive medical director of the Kansas City Heart Rhythm Institute, characterized the results as highly encouraging for the future of stroke risk reduction. With the device already holding a CE Mark in Europe and currently under FDA review, Abbott appears positioned to introduce a formidable competitor to the U.S. market in the near future.
Chronology of Innovation and Regulatory Milestones
The data presented at TCT 2024 is the culmination of years of iterative research and development. To understand the impact of these studies, it is necessary to view them within the chronological context of the cardiovascular device industry:
- 2011–2015: TAVR gains initial FDA approval for high-risk patients; renal denervation faces early clinical setbacks in the SYMPLICITY HTN-3 trial.
- 2019–2021: TAVR expands to low-risk patients; Abbott’s original Amulet receives FDA approval; Medtronic refines RDN trial designs to focus on "off-medication" and "on-medication" efficacy.
- 2023: Medtronic’s Symplicity Spyral and Recor’s Paradise RDN systems receive FDA approval, marking the commercial birth of the RDN market in the U.S.
- August 2024: Abbott receives the CE Mark for Amulet 360 in Europe.
- Late 2024 (TCT Conference): Edwards proves TAVR efficacy in moderate AS; Medtronic validates RDN in diverse real-world populations; Abbott releases one-year VERITAS data.
Broader Clinical and Economic Implications
The findings from TCT 2024 suggest a fundamental shift in cardiovascular medicine toward "early and definitive" intervention. For Edwards Lifesciences, the PROGRESS trial data could lead to a significant revision of clinical guidelines. If "watchful waiting" is replaced by early TAVR for moderate AS, the volume of procedures could double over the next decade, placing new demands on hospital infrastructure and "Heart Team" coordination.
For Medtronic, the SPYRAL AFFIRM data provides the necessary evidence for insurers to expand coverage for renal denervation. By proving that the technology works across different ethnicities and genders, Medtronic addresses a key concern of regulatory bodies regarding the generalizability of clinical trial results. The economic impact of reducing long-term hypertension—and by extension, the incidence of strokes and heart attacks—could result in billions of dollars in savings for global healthcare systems.
Finally, Abbott’s success with the Amulet 360 underscores the maturing of the LAA closure market. As AFib becomes more prevalent in an aging society, the demand for alternatives to anticoagulants is surging. The competition between Abbott and Boston Scientific is likely to drive further innovation in device delivery systems and imaging integration, ultimately benefiting patients through more precise and safer procedures.
In summary, the TCT conference in San Diego served as a testament to the rapid pace of innovation in interventional cardiology. By moving beyond the "low-hanging fruit" of end-stage disease and tackling the complexities of moderate conditions and diverse populations, Edwards, Medtronic, and Abbott are not only expanding their commercial reach but are also providing clinicians with the tools necessary to prevent cardiovascular crises before they occur. The next several years will likely see these study results translate into updated clinical guidelines, broader regulatory labels, and a new standard of care for millions of patients worldwide.
